The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
ITV's Tonight programme tracks down the Romanian criminal mastermind behind one of Britain’s biggest jewellery heist gangs.
The company has seen rocketing sales but still makes a loss, while calls to offer benefits to riders could make its model unviable.
Consumer group Which? has backed the fire brigade's call to end produced of 'fire risk' plastic backed fridges and freezers.